About ProstateProstate cancer is the most common form of cancer in men in the United States and is the second leading cause of cancer deaths in men every year. The American Cancer Society estimates that 234,000 new diagnosed with diagnosed with of prostate cancer, and that 30,000 people nationwide die from the disease in 2008. – About the License Agreement – offers A cooperation agreement between the wholly owned subsidiary Progenics Pharmaceuticals, PSMA Development Company and Seattle Genetics a worldwide license for proprietary SG antibody-drug conjugate – technology.
A cancer cell.Two – stage clinical trial designThe phase 1, open-label, dose – escalation trial will include as many as 40 men with progressive, hormone refractory prostate cancer, prior therapy prior therapy with taxane chemotherapy drugs. The study examined the duration of clinical benefit derived from PSMA ADC assessing assessing drug safety and tolerability. The initial 12-week period to evaluate up to four intravenous doses of PSMA ADC over five dose levels, three-week intervals three-week intervals.. – internalize the antibody-drug conjugate in the cancer cell, – release and thereby activate cancer drug, and – destroy the malignant cell.The cancer drug chemically bound to the antibody and is designed to be activated only after a cancer cell.A check-up Heart Transplant Ten years ConverselyConsider a cardiac transplant a decade ago, you find your body begins order which transplanted heart denied after so much time, and the physicians done the entire process the whole process so that your original heart working in you back. That is what happened to 12 – year-old Hanna Clark, UK.